Target
glycinamide ribonucleotide formyltransferase (GARFT)
5 abstracts
Abstract
Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): A single-center, single-arm, exploratory clinical trial.Org: The Affifiliated Hospital of Qingdao University,
Abstract
CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.Org: Juntendo University School of Medicine, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Hiroshima University, National Cancer Center Hospital Japan East, Kashiwa, Japan, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, The Second Hospital Affiliated to Air Force Medical University, Qilu Pharmaceutical,
Abstract
Management of tumor treating fields (TTFields) therapy-related skin adverse events in pleural mesothelioma: A single center experience of TTFields therapy concomitant with chemotherapy.Org: Mesothelioma Unit, SS Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy, Alessandria, Italy, Oncology Unit S. Chiara Hospital, Trento, Italy,
Abstract
Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial.Org: Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France, Institut Gustave Roussy, Villejuif, France, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain,